CY1119698T1 - Μεθοδοι και συνθεσεις για θεραπεια συμπτωματων που σχετιζονται με διαταραχη μετατραυματικου στρες χρησιμοποιωντας κυκλοβενζαπρινη - Google Patents

Μεθοδοι και συνθεσεις για θεραπεια συμπτωματων που σχετιζονται με διαταραχη μετατραυματικου στρες χρησιμοποιωντας κυκλοβενζαπρινη

Info

Publication number
CY1119698T1
CY1119698T1 CY20171101187T CY171101187T CY1119698T1 CY 1119698 T1 CY1119698 T1 CY 1119698T1 CY 20171101187 T CY20171101187 T CY 20171101187T CY 171101187 T CY171101187 T CY 171101187T CY 1119698 T1 CY1119698 T1 CY 1119698T1
Authority
CY
Cyprus
Prior art keywords
treatment
methods
stress disorder
cyclenzaprine
postgraduate
Prior art date
Application number
CY20171101187T
Other languages
English (en)
Inventor
Seth Lederman
Herb Harris
Original Assignee
Tonix Pharma Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44059887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tonix Pharma Holdings Limited filed Critical Tonix Pharma Holdings Limited
Publication of CY1119698T1 publication Critical patent/CY1119698T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μεθόδους για τη θεραπεία ή πρόληψη συμπτωμάτων που σχετίζονται με διαταραχή μετατραυματικού στρες, και με σχετικές φαρμακευτικές συνθέσεις. Ιδιαίτερο ενδιαφέρον παρουσιάζουν φαρμακευτικές συνθέσεις που περιέχουν πολύ χαμηλή δόση κυκλοβενζαπρίνης, μόνης ή σε συνδυασμό με έναν ανταγωνιστή αλφα-1 αδρενεργικού υποδοχέα, έναν βήτα-αδρενεργικό ανταγωνιστή, ένα αντισπασμωδικό, έναν εκλεκτικό αναστολέα επαναπρόσληψης σεροτονίνης ή έναν αναστολέα επαναπρόσληψης σεροτονίνης-νορεπινεφρίνης.
CY20171101187T 2009-11-20 2017-11-14 Μεθοδοι και συνθεσεις για θεραπεια συμπτωματων που σχετιζονται με διαταραχη μετατραυματικου στρες χρησιμοποιωντας κυκλοβενζαπρινη CY1119698T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28166109P 2009-11-20 2009-11-20
PCT/US2010/002979 WO2011062614A1 (en) 2009-11-20 2010-11-16 Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine

Publications (1)

Publication Number Publication Date
CY1119698T1 true CY1119698T1 (el) 2018-04-04

Family

ID=44059887

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101187T CY1119698T1 (el) 2009-11-20 2017-11-14 Μεθοδοι και συνθεσεις για θεραπεια συμπτωματων που σχετιζονται με διαταραχη μετατραυματικου στρες χρησιμοποιωντας κυκλοβενζαπρινη

Country Status (14)

Country Link
US (2) US9918948B2 (el)
EP (1) EP2501234B1 (el)
CY (1) CY1119698T1 (el)
DK (1) DK2501234T3 (el)
ES (1) ES2649022T3 (el)
HR (1) HRP20171739T1 (el)
HU (1) HUE037281T2 (el)
LT (1) LT2501234T (el)
NO (1) NO2501234T3 (el)
PL (1) PL2501234T3 (el)
PT (1) PT2501234T (el)
RS (1) RS56634B1 (el)
SI (1) SI2501234T1 (el)
WO (1) WO2011062614A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
WO2013188847A1 (en) * 2012-06-15 2013-12-19 Tonix Pharmaceuticals, Inc. Compositions and methods for transmucosal absorption
HRP20240648T1 (hr) 2013-03-15 2024-08-02 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin hidroklorida i manitola
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
CN118267382A (zh) * 2017-12-11 2024-07-02 通尼克斯制药控股有限公司 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
CA3109258A1 (en) * 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
WO2021207561A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
WO2022109218A1 (en) 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
EP0693924B2 (en) 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (pt) 1998-05-14 2003-04-30 Alza Corp Terapia anti-depressiva
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AR025110A1 (es) 1999-08-13 2002-11-06 Vela Pharmaceuticals Inc Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
BR0013122A (pt) 1999-08-13 2002-04-30 Vela Pharmaceuticals Inc Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001261744A1 (en) 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2003039525A1 (en) 2001-11-05 2003-05-15 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
KR20200083657A (ko) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
AU2004251647B2 (en) 2003-05-29 2010-01-14 Takeda Pharmaceutical Company Limited Abuse resistant amphetamine compounds
MXPA06005019A (es) 2003-11-03 2006-07-06 Warner Lambert Co Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central.
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1727520A2 (en) 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090069267A1 (en) * 2006-01-17 2009-03-12 Abrams Daniel J Central administration of stable formulations of therapeutic agents for cns conditions
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
WO2009002770A1 (en) * 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
NZ583193A (en) * 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
PT2611440T (pt) 2010-09-01 2017-04-26 Tonix Pharmaceuticals Inc Tratamento para a dependência de cocaína
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
WO2013188847A1 (en) 2012-06-15 2013-12-19 Tonix Pharmaceuticals, Inc. Compositions and methods for transmucosal absorption
HRP20240648T1 (hr) 2013-03-15 2024-08-02 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin hidroklorida i manitola
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride

Also Published As

Publication number Publication date
EP2501234A4 (en) 2013-04-24
US9918948B2 (en) 2018-03-20
EP2501234B1 (en) 2017-09-13
WO2011062614A1 (en) 2011-05-26
PT2501234T (pt) 2017-12-13
SI2501234T1 (en) 2018-02-28
HUE037281T2 (hu) 2018-08-28
RS56634B1 (sr) 2018-03-30
ES2649022T3 (es) 2018-01-09
HRP20171739T1 (hr) 2018-03-09
EP2501234A1 (en) 2012-09-26
NO2501234T3 (el) 2018-02-10
LT2501234T (lt) 2017-12-11
PL2501234T3 (pl) 2018-01-31
US20110124656A1 (en) 2011-05-26
DK2501234T3 (en) 2017-12-04
US20180193288A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CY1119698T1 (el) Μεθοδοι και συνθεσεις για θεραπεια συμπτωματων που σχετιζονται με διαταραχη μετατραυματικου στρες χρησιμοποιωντας κυκλοβενζαπρινη
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1118352T1 (el) Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1121183T1 (el) Νεες θεραπευτικες μεθοδευσεις για θεραπευτικη αγωγη cmt και συναφων διαταραχων
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1119952T1 (el) Συνδυασμος μιας ινσουλινης και ενος glp-1-αγωνιστη
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CY1119048T1 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CY1118530T1 (el) Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
UY33017A (es) Tratamiento para trastornos gastrointestinales
CR11418A (es) Trans-clomifeno para el sindrome metabolico